BioSpace News Archive

Knopp Biosciences LLC, a privately held drug discovery and development company focused on delivering breakthrough treatments for immunological and neurological diseases with high unmet need, today announced that data from its Kv7 platform will be presented at the American Epilepsy Society’s (AES) 2019 Annual Meeting from December 6-10 in Baltimore.

ADVANZ PHARMA Corp. (“ADVANZ PHARMA” or “the Company”) (TSX:ADVZ), an international specialty pharmaceutical company focused on serving the needs of patients and healthcare providers around the world with enhanced access to high quality, niche-established medicines, today announced that it will hold a special meeting of shareholders on December 17, 2019, at 10:00 am

CTT Pharmaceutical Holdings, Inc., (the “Company” or “CTT”) (OTC: CTTH), an innovative life sciences company with a portfolio of IP in novel drug delivery systems, announced today several additions to its Board of Directors and management team

Arvinas Inc. (Nasdaq: ARVN), a biotechnology company creating a new class of drugs based on targeted protein degradation, today announced that Ian Taylor, Ph.D., Chief Scientific Officer, will participate in a fireside chat at the 31st Annual Piper Jaffray Healthcare Conference on Thursday, December 5 at 12:00 p.m. ET in New York, NY.

Passage Bio, a genetic medicines company focused on developing transformative therapies for rare, monogenic central nervous system diseases, today announced that management will present at the Piper Jaffray 31st Annual Healthcare Conference on Thursday, December 5th, 2019 at 8:30 a.m. ET in New York, NY

Cardiologist and patient safety advocate, Dr. Robert Amyot, is joining the MEDFAR Clinical Solutions executive team as Chief Medical Officer, at a time when the company is expanding its presence across Canada and internationally.

The Company has scheduled a conference call beginning at 10 a.m. ET that day to discuss the results.

There is no cost for this test.

Only one in five people (22%) disagree with the statement “generally, patients with lung cancer have caused their illness through their lifestyle choices and behaviors,” according to a global, omnibus survey conducted by Ipsos MORI and sponsored by the Lung Ambition Alliance.

On August 27, we had the great pleasure of reporting successful top line results in the phase IIb study CONDUCT with cobitolimod.